Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1975 2
1976 1
1982 1
1983 1
1986 1
1987 2
1990 2
1991 1
1993 2
1995 1
1997 2
1998 2
1999 1
2000 1
2001 1
2002 5
2003 8
2004 24
2005 23
2006 18
2007 23
2008 21
2009 19
2010 22
2011 11
2012 16
2013 17
2014 21
2015 22
2016 35
2017 25
2018 20
2019 26
2020 19
2021 15
2022 13
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
Concerns about the ALIFE2 trial.
Yanagisawa R, Fujiwara SI, Sato T. Yanagisawa R, et al. Lancet. 2024 Jan 20;403(10423):246-247. doi: 10.1016/S0140-6736(23)02339-5. Lancet. 2024. PMID: 38245242 No abstract available.
Insulin resistance and bariatric surgery.
Rao RS, Yanagisawa R, Kini S. Rao RS, et al. Among authors: yanagisawa r. Obes Rev. 2012 Apr;13(4):316-28. doi: 10.1111/j.1467-789X.2011.00955.x. Epub 2011 Nov 23. Obes Rev. 2012. PMID: 22106981 Review.
Metabolic management following bariatric surgery.
Strohmayer E, Via MA, Yanagisawa R. Strohmayer E, et al. Among authors: yanagisawa r. Mt Sinai J Med. 2010 Sep-Oct;77(5):431-45. doi: 10.1002/msj.20211. Mt Sinai J Med. 2010. PMID: 20960547 Review.
The REVAMP trial: key questions remain.
Sato T, Yanagisawa R. Sato T, et al. Among authors: yanagisawa r. Lancet. 2024 Jan 6;403(10421):28-29. doi: 10.1016/S0140-6736(23)01919-0. Lancet. 2024. PMID: 38184334 No abstract available.
Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients.
Tamaki M, Akahoshi Y, Okada Y, Uchida N, Tanaka M, Doki N, Sawa M, Maruyama Y, Ueda Y, Miyakoshi S, Katayama Y, Kawakita T, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Kanda J, Nakasone H. Tamaki M, et al. Among authors: yanagisawa r. Cytotherapy. 2023 Nov;25(11):1220-1228. doi: 10.1016/j.jcyt.2023.06.002. Epub 2023 Jun 20. Cytotherapy. 2023. PMID: 37341665
Comparative Analysis of Allogeneic Bone Marrow Transplantation Outcomes Between Japanese and Non-Japanese Populations.
Yanagisawa R, Shindo M, Shinohara A, Kuwatsuka Y, Nakase K, Kimura F, Shingai N, Nishida T, Fukuda T, Sakurai M, Kurokawa M, Koike T, Ota S, Takada S, Onizuka M, Uchida N, Tanaka M, Noguchi M, Maruyama Y, Hagihara M, Ichinohe T, Atsuta Y, Kanda J, Nakasone H, Toubai T. Yanagisawa R, et al. Transplant Proc. 2024 Mar;56(2):416-421. doi: 10.1016/j.transproceed.2024.01.049. Epub 2024 Feb 9. Transplant Proc. 2024. PMID: 38336483
Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.
Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, Ikegame K, Matsuoka KI, Katayama Y, Kanda Y, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Shinohara A, Nakasone H. Yanagisawa R, et al. Bone Marrow Transplant. 2024 Mar;59(3):325-333. doi: 10.1038/s41409-023-02172-4. Epub 2023 Dec 16. Bone Marrow Transplant. 2024. PMID: 38104219
378 results